PTC Therapeutics Announced An Agreement With Royalty Pharma To Monetize Up To $1.5B Of The Evrysdi Royalty Stream. Under The Agreement, Royalty Pharma Acquires Additional Royalties On Evrysdi For $1B Upfront
Portfolio Pulse from Benzinga Newsdesk
PTC Therapeutics has entered into an agreement with Royalty Pharma to monetize up to $1.5B of the Evrysdi royalty stream. Royalty Pharma will acquire additional royalties on Evrysdi for $1B upfront. The agreement also includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.
October 19, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Royalty Pharma has entered into an agreement with PTC Therapeutics to acquire additional royalties on Evrysdi for $1B upfront.
While the agreement provides Royalty Pharma with additional royalties, it also requires a significant upfront payment. The impact on the company's stock price will depend on how the market perceives the value of these additional royalties compared to the upfront cost.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
PTC Therapeutics has entered into a significant agreement with Royalty Pharma, which could provide a substantial influx of cash for the company.
The agreement with Royalty Pharma could provide a significant cash influx for PTC Therapeutics, which could be used for various purposes such as research and development, paying down debt, or returning capital to shareholders. This could potentially have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100